Progenics Pharmaceuticals Inc./Salix Pharmaceuticals Ltd.’s drawn-out pursuit of an expanded indication for their subcutaneous peripherally-acting mu opioid receptor antagonist Relistor for opioid-induced constipation in chronic, non-cancer pain patients has finally ended in success, but its non-oral formulation has it at a competitive disadvantage.
The Sept. 29 approval of the sNDA for subcutaneous Relistor (methylnaltrexone) followed on the heels of FDA’s Sept. 16 clearance...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?